Abstract
Lys49-phospholipase A2 homologues constitute a large family of toxins present in the venoms of viperid snake species, which despite lacking catalytic activity, cause significant skeletal muscle necrosis. The main structural determinants of this toxic effect have been experimentally mapped to a region near their C-terminus (115-129), which combines cationic and hydrophobic/aromatic amino acid residues. Short (13-mer) synthetic peptides representing this C-terminal region can mimick several of the effects of Lys49 PLA2 homologues. In addition to their ability to damage muscle cells, these peptides display antibacterial, antiendotoxic, antifungal, antiparasite, and antitumor activities, as well as VEGF-receptor 2 (KDR)-binding and heparin-binding properties. Modifications of their sequences have shown possibilities to enhance their effects upon prokaryotic cells, while decreasing toxicity for eukaryotic cells. This review presents an updated summary on the biomimetic actions exerted by such peptides, and highlights their potential value as molecular tools or as drug leads in diverse biomedical areas.
Keywords: Synthetic peptides, phospholipase A2, snake venom, biomimetic, antimicrobial, antitumor, VEGF, heparin
Current Pharmaceutical Design
Title: Synthetic Peptides Derived from the C-Terminal Region of Lys49 Phospholipase A2 Homologues from Viperidae Snake Venoms: Biomimetic Activities and Potential Applications
Volume: 16 Issue: 28
Author(s): Bruno Lomonte, Yamileth Angulo and Edgardo Moreno
Affiliation:
Keywords: Synthetic peptides, phospholipase A2, snake venom, biomimetic, antimicrobial, antitumor, VEGF, heparin
Abstract: Lys49-phospholipase A2 homologues constitute a large family of toxins present in the venoms of viperid snake species, which despite lacking catalytic activity, cause significant skeletal muscle necrosis. The main structural determinants of this toxic effect have been experimentally mapped to a region near their C-terminus (115-129), which combines cationic and hydrophobic/aromatic amino acid residues. Short (13-mer) synthetic peptides representing this C-terminal region can mimick several of the effects of Lys49 PLA2 homologues. In addition to their ability to damage muscle cells, these peptides display antibacterial, antiendotoxic, antifungal, antiparasite, and antitumor activities, as well as VEGF-receptor 2 (KDR)-binding and heparin-binding properties. Modifications of their sequences have shown possibilities to enhance their effects upon prokaryotic cells, while decreasing toxicity for eukaryotic cells. This review presents an updated summary on the biomimetic actions exerted by such peptides, and highlights their potential value as molecular tools or as drug leads in diverse biomedical areas.
Export Options
About this article
Cite this article as:
Lomonte Bruno, Angulo Yamileth and Moreno Edgardo, Synthetic Peptides Derived from the C-Terminal Region of Lys49 Phospholipase A2 Homologues from Viperidae Snake Venoms: Biomimetic Activities and Potential Applications, Current Pharmaceutical Design 2010; 16 (28) . https://dx.doi.org/10.2174/138161210793292456
DOI https://dx.doi.org/10.2174/138161210793292456 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics
Reviews on Recent Clinical Trials Epithelial Mesenchymal Transition in Cancer Progression: Prev entive Phytochemicals
Recent Patents on Anti-Cancer Drug Discovery The p53-Mdm2 Pathway: Targets for the Development of New Anticancer Therapeutics
Mini-Reviews in Medicinal Chemistry The Role of Image Guided Radiotherapy in the Treatment of Soft Tissue Sarcoma
Current Cancer Therapy Reviews Pretreatment with Gallic Acid Mitigates Cyclophosphamide Induced Inflammation and Oxidative Stress in Mice
Current Molecular Pharmacology Current Status and Perspectives in Peptide Receptor Radiation Therapy
Current Pharmaceutical Design Hybrid Organic-Inorganic Scaffolding Biomaterials for Regenerative Therapies
Current Organic Chemistry Meet Our Editorial Board Member
Letters in Drug Design & Discovery Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma
Current Cancer Therapy Reviews CSPG4 in Cancer: Multiple Roles
Current Molecular Medicine Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer
Current Cancer Drug Targets Cytochrome P450 Structure, Function and Clinical Significance: A Review
Current Drug Targets Lectin-Carbohydrate Interactions: Implications for the Development of New Anticancer Agents
Current Medicinal Chemistry Highly Selective MEK Inhibitors
Current Enzyme Inhibition Cytokine Antibody Arrays in Biomarker Discovery and Validation
Current Proteomics Oxidative Stress in Tumor Angiogenesis - Therapeutic Targets
Current Pharmaceutical Design Development of a Substrate Identification Method for Human Scp1 Phosphatase Using Phosphorylation Mimic Phage Display
Protein & Peptide Letters Diffusion-Weighted Imaging in Abdominal Oncology
Current Medical Imaging Can Dietary Antioxidants Reduce the Incidence of Brain Tumors?
Current Drug Metabolism FTD and ALS: A Tale of Two Diseases
Current Alzheimer Research